Industry Briefs: Mar. 26, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Industry Briefs: Mar. 26, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Mar 29, 2012

Company News

Corcept Therapeutics has selected PharmaForm as its primary commercial manufacturer for its newly approved drug product, Korlym (mifepristone) for treating Cushing’s syndrome. Read More

Coronado Biosciences has signed a collaboration agreement with Dr. Falk Pharma and OvaMed for the development of trichuris suis ova for treating Crohn’s Disease. Read More

Elite Pharmaceuticals has signed an agreement with a private Hong Kong-based company to develop a branded prescription pharmaceutical product in the US. Read More

GE Healthcare has expanded its Shanghai Fast Trak training center to serve the growing biopharmaceutical industry in China.

Impax and Tolmar have multiproduct agreement for the development, supply, and distribution of alternative dosage-form products. Read More

Marken has completed all commissioning work for its new operational hub in Feltham, United Kingdom. Read More

People News

Adhesives Research appointed Steven Herbert to the position of manufacturing manager.

Albany Molecular Research has named Stephen Rossmeis senior manager to oversee the company's facilities at Burlington, Massachusetts aseptic-fill operations. Read More

Avrio Biopharmaceuticals has appointed William P. Botha as president. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Featured Jobs

More Jobs
3/29/2012
 Click here